Sanjivani Paranteral Q1 FY27 PAT rises 44% to ₹2.49 crore

Key takeaway from the June-quarter print

Sanjivani Paranteral Ltd reported a sharp year-on-year rise in earnings for the quarter ended June 30, 2026 (Q1 FY27), led by higher consolidated revenue and improved profitability. The company declared unaudited consolidated financial results for the period, showing a 44% increase in consolidated profit after tax (PAT). Consolidated revenue from operations also expanded at a faster pace than profit, pointing to stronger scale during the quarter.

The numbers are relevant for investors tracking smaller pharmaceutical manufacturers where quarterly execution and order flows can cause meaningful swings in margins and earnings. The result also comes with an improvement in earnings per share (EPS), a key per-share indicator closely watched in smaller-cap names.

Consolidated results: profit up 44%, revenue up about 33%

On a consolidated basis, Sanjivani Paranteral reported PAT of ₹2.49 crore in Q1 FY27, up from ₹1.73 crore in Q1 FY26. Revenue from operations rose to ₹23.84 crore from ₹17.89 crore over the same period. The company also disclosed that basic and diluted EPS improved to ₹2.03 from ₹1.46.

The headline performance suggests that the company was able to translate higher revenue into higher profit, with EPS growth reflecting that improvement at the per-share level. The figures were reported as consolidated and unaudited for the quarter ended June 30, 2026.

Standalone performance: steady revenue, higher profit

The company also reported standalone numbers for the quarter ended June 30, 2026. Standalone net profit rose 32.6% year-on-year to ₹2.2954 crore (₹229.54 lakh). Revenue from operations increased 8.7% to ₹19.4584 crore (₹1,945.84 lakh).

In addition, the company disclosed consolidated net profit attributable to owners of ₹2.4128 crore (₹241.28 lakh), up 39.1% from ₹1.7306 crore (₹173.06 lakh). Consolidated revenue from operations was also presented as ₹23.8392 crore (₹2,383.92 lakh), up 33.2% year-on-year.

EPS improvement adds support to the quarterly print

Alongside profit and revenue growth, EPS rose to ₹2.03 in Q1 FY27 from ₹1.46 a year earlier. This matters because EPS captures the earnings available per share and is often used for comparing performance across periods.

The company also has a separate set of quarterly EPS figures in its historical data, where adjusted EPS is shown at ₹1.46 for June 2025 and ₹0.76 for March 2026, based on a table labelled “Quarterly Result (All Figures in Cr.)”.

Recent quarterly trend: March 2026 was weaker on net sales

A separate quarterly table in the provided data set shows that net sales were ₹10.51 crore for March 2026, down 42.19% year-on-year (as stated). In the same table, net sales for December 2025 were ₹20.86 crore, while June 2025 net sales were ₹17.89 crore.

This context is important because Q1 FY27 (June 2026 quarter) consolidated revenue from operations was reported at ₹23.84 crore, which indicates a stronger top line compared with the March 2026 net sales number shown in the historical quarterly snapshot.

Snapshot of key disclosed numbers

Corporate-action page data: sales, costs and EPS history

The “Quarterly Result (All Figures in Cr.)” table included in the material lists net sales, expenditure, operating profit, tax and PAT for multiple quarters up to March 2026. It shows PAT of ₹1.73 crore for June 2025 and PAT of ₹0.94 crore for March 2026, along with adjusted EPS of ₹1.46 for June 2025 and ₹0.76 for March 2026.

These historical disclosures provide a reference frame for how profits and EPS have moved quarter to quarter, although the latest reported Q1 FY27 figure cited separately is on a consolidated basis.

Guidance and operational commentary referenced in the dataset

The provided text also includes FY27 guidance figures, including total revenue guidance of ₹80-85 crore from the base business and ₹60-65 crore from the Pune IV plant. It also lists expected EBITDA margins of 15.5% to 16.5% for the base business and 17% to 18% for the IV business, with break-even expected in FY27. A utilisation ramp for the IV facility is also referenced, moving from 40% and 45% to 60% and 70% by the fourth quarter.

These guidance items, as presented, indicate the company is tracking separate revenue and margin targets for a base business and a Pune IV plant.

Share price and upcoming earnings date

The dataset states: “The current share price of Sanjivani Paranteral is Rs 166.” It also mentions “Earnings: Expected on 14/08/2026.” These two points provide a near-term reference for market participants watching the earnings calendar and the stock’s latest stated price level.

Note on other pharma results appearing in the same material

The supplied text bundle also contains a separate set of quarterly financial metrics and commentary for Sai Parenterals Ltd, including consolidated revenue of ₹182.4 crore and standalone PAT of ₹8.9 crore for Q1 FY27, with details about consolidation of Noumed Pharmaceuticals. Those figures are presented under the Sai Parenterals name and are distinct from Sanjivani Paranteral’s Q1 FY27 consolidated revenue of ₹23.84 crore and PAT of ₹2.49 crore.

Conclusion

Sanjivani Paranteral’s Q1 FY27 update showed faster year-on-year growth in consolidated revenue and a 44% rise in consolidated PAT to ₹2.49 crore, with EPS increasing to ₹2.03. The dataset also references FY27 revenue and margin guidance for the base business and the Pune IV plant, and lists an earnings date expected on August 14, 2026.